The researchers’ analysis showed low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease. Also, transcriptome-wide association in lung tissue revealed that high expression of the monocyte–macrophage chemotactic receptor CCR2 is associated with severe COVID-19.
The PD-1 checkpoint inhibitor Opdivo (nivolumab) has been approved by the FDA as an initial treatment for advanced gastric cancer, adding to its approvals as a treatment for melanoma and a number of other cancers.
Already a leader among U.S. health systems in using genomics to guide care, the strategic alliance between NorthShore and Sema4 will significantly expand NorthShore’s existing clinical genomics offerings to more than 1,000 physicians and approximately 300,000 NorthShore patients.
The study brings to light a novel disorder resulting from disruption of a gene that plays a critical role in the maintenance of mitochondrial DNA.
The researchers found that mutations in KMT2C and KMT2D make non-small cell lung cancer more sensitive to Poly (ADP-ribose) polymerase (PARP) inhibitors, which are already approved for treating prostate, pancreatic, ovarian, and breast cancer patients.
A new sweat sensor can detect seven inflammatory proteins seen at high levels in patients experiencing the kind of extreme immune reaction seen in COVID-19 and in some flu patients, which researchers hope will speed up treatment.
The research team drew from Mount Sinai's BioMe BioBank program, a repository of genomic information for diverse populations, for its study. Using machine learning methodology, they identified 17 distinct ethnic communities from among the 30,000 participants in the BioMe BioBank.
A team of researchers from Centre de Recherche en Cancerologie de Marseille (CRCM), INSERM in France have developed a new method for capturing the metabolic signature of pancreatic ductal adenocarcinoma to predict clinical outcomes.
Thermo Fisher said the acquisition would establish it as a global leader in a clinical research industry it pegged at $50 billion, by positioning it for growth as biopharmas work to commercialize discoveries by investing more in drug discovery, and as smaller biopharmas show increasing need for services furnished by strategic suppliers.
A Spanish study shows epigenetic markers in the DNA can predict COVID-19 disease severity. Many of these markers are found in genes linked to immune function and the release of interferon in response to viral infection such as AIM2 and HLA-C.